Cold Spring Harbor Laboratory

Cold Spring Harbor Laboratory (CSHL) is a private, non-profit institution dedicated to biomedical research and education, headquartered in Laurel Hollow, New York. Established in 1890, its core mission is to power transformational discoveries in various biological fields by educating and empowering scientific pioneers, ultimately aiming to improve human quality of life by pushing the boundaries of science.

CSHL conducts extensive research across key areas including cancer, neuroscience, plant biology, genomics, quantitative biology, molecular biology, and artificial intelligence. Beyond research, the institution offers a range of educational programs, including a Ph.D. program through its School of Biological Sciences, an Undergraduate Research Program, and the DNA Learning Center for K-12 education. CSHL also hosts numerous scientific meetings and courses, such as the Cold Spring Harbor Symposium series and the Banbury Center, fostering global scientific collaboration. Additionally, its publishing arm, Cold Spring Harbor Laboratory Press, disseminates scientific knowledge through journals, books, and online resources, including the preprint servers bioRxiv and medRxiv.

Led by President and CEO Bruce Stillman, Ph.D., Cold Spring Harbor Laboratory maintains a prominent position in the scientific community. Recent notable developments include a multimillion-dollar endowment in April 2026 from philanthropist Cynthia Stebbins, matched by Marilyn Simons, to support CSHL Fellows in cancer biology and AI research. In the same month, the institution's Graduate School received national recognition, ranking as the number one Best Grad School in U.S. News and World Report's 2026 rankings. CSHL is recognized as an NCI-designated Cancer Center and has been ranked first globally in molecular biology and genetics research output by Thomson Reuters and Nature, respectively.

Latest updates

CSHL's 'Cheese3D' Offers New Window into Brain-Behavior Link

Event summary

  • Cold Spring Harbor Laboratory (CSHL) has developed 'Cheese3D,' a new system for tracking and quantifying facial expressions in mice.
  • The system utilizes six high-speed cameras and AI to capture 3D motion of the entire mouse face, including ears, eyes, and whiskers.
  • Cheese3D has demonstrated accuracy comparable to EEG methods in assessing mouse anesthesia levels without disturbance.
  • The research, published in Nature Neuroscience, was led by Assistant Professor Helen Hou and collaborators Kyle Daruwalla and Irene Nozal Martin.

The big picture

The development of Cheese3D addresses a longstanding challenge in neuroscience: the lack of precise, quantitative methods for studying the link between facial expression and brain activity. This technology could accelerate research into neurological disorders, anesthesia management, and developmental psychology, potentially opening new avenues for therapeutic intervention. While currently focused on mice, the underlying principles could be adapted for human applications, though significant technical hurdles remain.

What we're watching

Clinical Translation
The applicability of Cheese3D to human facial expression analysis and disease state monitoring remains to be seen, and will be a key indicator of long-term value.
Behavioral Insights
The ability to quantify facial expressions could significantly advance understanding of social development, particularly in conditions like autism, but requires robust validation across diverse populations.
Competitive Landscape
While Cheese3D appears novel, the emergence of competing automated facial expression analysis tools in both animal models and human applications is likely, potentially impacting CSHL's licensing and commercialization opportunities.

Immune Response Link to Brain Disease Could Reshape Cancer Treatment

Event summary

  • Cold Spring Harbor Laboratory (CSHL) researchers have linked the body’s immune response to cancer with the development of autoimmune brain diseases like anti-NMDA receptor encephalitis (ANRE).
  • A mouse model of breast cancer revealed that antibodies generated to fight tumors can also trigger seizures and neurological damage when introduced into healthy brains.
  • Cryo-EM analysis showed that the same antibodies can either activate or inhibit NMDA receptors, highlighting the dual nature of the immune response.
  • A study of triple-negative breast cancer patients found that approximately 15% had antibodies targeting NMDA receptors and demonstrated better clinical outcomes, suggesting immune system activity against the cancer.
  • The research, published in Nature on March 25, 2026, suggests a potential new avenue for antibody-based cancer treatments.

The big picture

This research challenges the conventional understanding of cancer treatment by revealing a complex interplay between the immune system and neurological health. The discovery could lead to a paradigm shift in cancer therapy, moving beyond targeted therapies to harness the body’s own defenses while mitigating unintended consequences. The findings also highlight the potential for autoimmune diseases to be linked to underlying, often undetected, cancers, opening new avenues for diagnostic screening and preventative medicine.

What we're watching

Treatment Efficacy
The success of future antibody-based cancer therapies will depend on the ability to selectively target tumor-specific antibodies while minimizing neurological side effects, requiring refined targeting strategies.
Clinical Validation
Further clinical trials are needed to validate the correlation between NMDA receptor antibodies and improved outcomes in triple-negative breast cancer patients, and to determine if this is a broadly applicable phenomenon across other cancer types.
Regulatory Pathway
Regulatory agencies will likely scrutinize the potential neurological risks associated with antibody-based cancer therapies, potentially requiring extensive safety monitoring and risk mitigation strategies.

Shrinking AI Models Unlock Insights into Primate Brain Function

Event summary

  • Cold Spring Harbor Laboratory researchers, led by Assistant Professor Benjamin Cowley, have developed a significantly smaller AI model that accurately replicates monkey vision.
  • The new model is approximately 1/1,000 the size of current state-of-the-art AI systems while maintaining superior performance in predicting neural responses.
  • The research, published in Nature, involved training large AI models on macaques and then compressing them using advanced technology.
  • Analysis of the compact model revealed that neurons process images by breaking them down into low-level features and consolidating information, highlighting the specialization of neurons (e.g., 'dot-loving' neurons).

The big picture

This research represents a significant shift in AI development for neuroscience, moving away from resource-intensive, large-scale models towards more targeted and interpretable approaches. By focusing on replicating the efficiency of biological systems, Cowley's work could unlock a deeper understanding of brain function and potentially pave the way for novel therapeutic interventions, challenging the prevailing trend of ever-larger AI models for general intelligence.

What we're watching

Therapeutic Applications
The potential for applying these AI models to understand and potentially treat neurodegenerative diseases like Alzheimer's dementia warrants close observation, particularly as the technology matures and image-driven therapeutic interventions are explored.
Model Scalability
The ability to replicate this compression and analytical approach across more complex brain functions and species will determine the broader applicability of the methodology.
Ethical Implications
As AI models become increasingly sophisticated in mimicking brain function, scrutiny regarding data privacy and the potential for misuse in areas like behavioral manipulation will likely intensify.

CSHL Research Uncovers Nerve-Tumor Loop in Pancreatic Cancer, Opens New Therapeutic Avenues

Event summary

  • Cold Spring Harbor Laboratory (CSHL) researchers have identified a previously unknown interaction between pancreatic cancer cells and the sympathetic nervous system.
  • Using 3D imaging and mouse models, the team discovered that myCAFs (tumor-promoting fibroblasts) attract nerve fibers, creating a self-reinforcing loop that promotes pre-cancerous growth.
  • Disrupting this nerve-CAF interaction with a neurotoxin resulted in a nearly 50% reduction in tumor growth in mice.
  • The research, published in *Cancer Discovery*, suggests existing drugs like doxazosin may be effective when combined with standard cancer treatments.

The big picture

Pancreatic cancer remains a significant unmet medical need with notoriously poor survival rates. This discovery shifts the focus beyond traditional tumor-centric approaches, highlighting the potential of targeting the tumor microenvironment and the nervous system's role in cancer progression. The identification of a druggable target within this newly understood pathway could represent a paradigm shift in treatment strategies, potentially impacting a market with significant unmet need and high treatment costs.

What we're watching

Therapeutic Validation
The efficacy of repurposing existing drugs like doxazosin in combination therapies will be a key indicator of the research's translational potential and near-term commercial impact.
Mechanism Elucidation
Further investigation into the precise molecular mechanisms driving the myCAF-nerve crosstalk will be crucial for developing targeted therapies that specifically disrupt this loop.
Clinical Adoption
The pace at which oncologists adopt this new understanding of the nervous system's role in pancreatic cancer will dictate the speed of clinical trial enrollment and potential regulatory approvals.

Cold Spring Harbor Lab Identifies PTP1B Inhibition as Potential Alzheimer's Therapeutic

Event summary

  • Cold Spring Harbor Laboratory researchers, led by Professor Nicholas Tonks, have identified PTP1B inhibition as a potential therapeutic approach for Alzheimer's disease.
  • The research, conducted on a mouse model, demonstrated that inhibiting PTP1B improves learning and memory by enhancing the ability of microglia (brain’s immune cells) to clear amyloid-β plaques.
  • The Tonks lab is collaborating with DepYmed, Inc. to develop PTP1B inhibitors for various applications, including Alzheimer's disease.
  • PTP1B has been studied by Tonks since 1988, and its interaction with SYK, which regulates microglia, was found to be key to the observed effect.

The big picture

The Alzheimer's disease market represents a significant unmet medical need, with global costs estimated to be in the trillions. Current therapies offer limited benefits, creating an opportunity for novel approaches like PTP1B inhibition. The collaboration with DepYmed suggests a potential pathway for commercialization, but the inherent risks of drug development remain substantial.

What we're watching

Clinical Translation
The transition from mouse model efficacy to human clinical trials will be critical, as Alzheimer’s drug development has a notoriously high failure rate.
Regulatory Pathway
Given the complexity of Alzheimer’s pathology, regulatory agencies may require extensive data demonstrating both efficacy and safety before approving PTP1B inhibitors.
Combination Therapy
The envisioned combination therapy approach, pairing PTP1B inhibitors with existing Alzheimer's drugs, will require careful evaluation of synergistic effects and potential adverse interactions.

Cold Spring Harbor Lab Adds Venture Capitalist, Real Estate Executive to Board

Event summary

  • Cold Spring Harbor Laboratory (CSHL) has appointed Jack Abraham, founder and CEO of venture studio Atomic, and Terri Keogh, President and CEO of Castro Properties, to its Board of Trustees.
  • Jack Abraham's Atomic has backed companies including Hims & Hers (valuation exceeding $1 billion) and has co-founded dozens of businesses.
  • Terri Keogh recently repositioned Castro Properties’ flagship property in New York's Flatiron District to capitalize on the tech market.
  • Keogh previously served as President of the CSHL Association, replacing Mark Hamer, who remains on the Board.
  • CSHL is a 501(c)(3) public charity focused on biomedical research and education.

The big picture

The appointments of Jack Abraham and Terri Keogh represent a strategic shift for Cold Spring Harbor Laboratory, bringing in expertise from the venture capital and commercial real estate worlds. This move suggests a desire to enhance the lab's commercial viability and adapt to the evolving landscape of biomedical research, where funding pressures and competition are intensifying. The addition of Abraham, in particular, signals a potential focus on translating research into marketable products and services, which could alter the institution's long-term funding model and operational priorities.

What we're watching

Strategic Alignment
Abraham’s venture capital experience may push CSHL to explore commercialization opportunities beyond traditional research grants and licensing, potentially impacting its non-profit mission.
Real Estate Impact
Keogh’s expertise could influence CSHL’s long-term facility strategy, particularly regarding its real estate holdings on Long Island, as the lab navigates evolving research space needs.
Governance Evolution
The shift in leadership within the CSHL Association and the addition of Abraham signal a potential move towards a more business-oriented governance model for the institution.
CID: 2933